Both show anti-inflammatory potential

Healthcare providers must conduct comprehensive testing to definitively diagnose pancreatitis and assess its severity through: Serum Lipase Testing : The gold standard diagnostic marker, with levels three times above normal indicating pancreatitis, remaining elevated for 8-14 days providing a wider diagnostic window than amylase Serum Amylase Measurement : Rises within 3-6 hours of onset but normalizes within 5 days, making it less reliable for delayed presentations common in Ozempic users Magnetic Resonance Imaging (MRI) : Superior to CT for detecting early pancreatic changes and assessing ductal anatomy, with 92% diagnostic sensitivity Gastric Emptying Scintigraphy : Four-hour solid-phase study required to diagnose gastroparesis, typically performed after acute pancreatitis resolution when motility symptoms persist Complete Metabolic Panel : Evaluates organ function, electrolyte imbalances, and severity markers including BUN, creatinine, and calcium levels According to guidelines from the American College of Gastroenterology, the diagnosis of acute pancreatitis requires two of three criteria: Characteristic abdominal pain

Abecma carries a boxed warning for cytokine release syndrome, neurologic toxicities, HLH/MAS, prolonged cytopenia and secondary hematologic malignancies
DPP-4 inhibitors such as vildagliptin indirectly raise endogenous GLP-1 levels by preventing its breakdown, but they also affect other substrates
This dual approach provides more comprehensive inflammatory control than either alone, potentially reducing healing time further
Other Ingredients: Mannitol, stearic acid, citric acid, silicon dioxide, natural cherry flavor, croscarmellose sodium, and magnesium stearate